Endotherm Life Science Molecules (www.endotherm-lsm.com) serves as a Contract Research Organisation (CRO), providing medicinally relevant small molecules for drug discovery and the early phases of drug development.

The company holds a fully equipped state-of-the-art laboratory in the Science Park on the campus of the University of the Saarland in Saarbruecken/Germany. The team of Endotherm consists of 10 highly skilled chemists and technicians, trained in medicinal and synthetic organic chemistry. Endotherm is mainly involved with hit-finding, hit-to-lead and lead optimization studies with the aim to discover new drugs for unmet medical needs. Unique compound collections of small molecule libraries in wide diversity have been accumulated in recent years. The company has appropriate scientific personnel, tools and equipment (including automation technology) available for rational drug design, for the synthesis of new molecules, for biochemical evaluation of compounds (*in silico* ADMET-characterisation of compounds), and has access to a wide range of analytical instrumentation.

Particularly, we provide

- diversified and focused small molecule compound libraries for screening (up to 1000 compounds in >95% purity and availability of back-up material for re-supply)
- exclusive synthesis of series of up to 100 compounds around one given scaffold for lead optimization studies
- building blocks
- reference compounds
- exclusive synthesis of compounds up to 1 kg on demand
- natural products (Vitamin D derivatives, steroids, etc.)
- fluorescent probes and other reagents to be used for biochemical assays

Additionally, the company is involved with its own original drug discovery programs within various collaborations:

- EU-FP6/7 funded integrated research projects, which consist of approximately 20 partners each. The consortia have the aim to understand signalling pathways related to heart failure, arrhythmias and sudden cardiac death. Endotherm develops modulators of newly identified tagets with the aim to develop novel therapeutic rationales and diagnostic tools

- Various projects together with the University Heidelberg/Germany in the field of Hepatitis C Virus NS3 Protease, Dengue Virus NS3 Serine Protease and new antibiotics (MurA-Inhibitors)

With the aim to proceed with its original drug discovery programes more rapidly and to commercially exploit scientific research results as soon as possible, the company is interested in finding partners interested to provide equity capital in the range of 250-500T€.